{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0004976,73,MONDO:0004976,178,0]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0004976","source":"MONDO:0004976|amyotrophic lateral sclerosis","targets":["NCT00542412|CARE Canadian ALS Riluzole Evaluation|COMPLETED|PHASE4|INTERVENTIONAL","NCT00560287|Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00613899|Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)|COMPLETED|PHASE4|INTERVENTIONAL","NCT04997954|EMERALD TRIAL Open Label Extension Study|UNKNOWN|PHASE4|INTERVENTIONAL","NCT06849115|Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations|COMPLETED|PHASE4|INTERVENTIONAL","NCT07223723|A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)|RECRUITING|PHASE4|INTERVENTIONAL","NCT00021697|Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT00035815|Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial|COMPLETED|PHASE3|INTERVENTIONAL","NCT00047723|Minocycline to Treat Amyotrophic Lateral Sclerosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT00069186|Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00114530|Scleroderma: Cyclophosphamide or Transplantation|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00125203|Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00136110|Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT00330681|Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00349622|Clinical Trial Ceftriaxone in Subjects With ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT00353665|Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00372879|Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT00386464|Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00415519|Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III|COMPLETED|PHASE3|INTERVENTIONAL","NCT00424463|Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00444613|A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00445172|A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00706147|Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00818389|Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT00833820|Repetitive Transcranial Magnetic Stimulation (rTMS) in Amyotrophic Lateral Sclerosis|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00839033|Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders|TERMINATED|PHASE3|INTERVENTIONAL","NCT00868166|Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT00876772|Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00965497|Escitalopram (Lexapro) for Depression MS or ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT01016522|Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)|TERMINATED|PHASE3|INTERVENTIONAL","NCT01160263|Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls|COMPLETED|PHASE3|INTERVENTIONAL","NCT01281189|Phase 3 Study of Dexpramipexole in ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT01285583|Safety Extension Study of TRO19622 in ALS|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01492686|Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT01583088|Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation|TERMINATED|PHASE3|INTERVENTIONAL","NCT01622088|Phase 3 Extension Study of Dexpramipexole in ALS|TERMINATED|PHASE3|INTERVENTIONAL","NCT01776970|Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01825551|The Effect of GCSF in the Treatment of ALS Patients|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01933321|Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02496767|Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year|COMPLETED|PHASE3|INTERVENTIONAL","NCT02588677|Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02623699|An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE3|INTERVENTIONAL","NCT02936635|A Study for Patients Who Completed VITALITY-ALS (CY 4031)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03068754|Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT03127267|Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients|RECRUITING|PHASE3|INTERVENTIONAL","NCT03280056|Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients|COMPLETED|PHASE3|INTERVENTIONAL","NCT03293069|Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT03491462|Arimoclomol in Amyotropic Lateral Sclerosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT03505021|Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT03548311|Clinical Trial of Ultra-high Dose Methylcobalamin for ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT03690791|Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease|UNKNOWN|PHASE3|INTERVENTIONAL","NCT03800524|Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS|UNKNOWN|PHASE3|INTERVENTIONAL","NCT03836716|Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial|TERMINATED|PHASE3|INTERVENTIONAL","NCT03948178|Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension|TERMINATED|PHASE3|INTERVENTIONAL","NCT04057898|Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT04082832|CuATSM Compared With Placebo for Treatment of ALS/MND|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT04165824|Safety Study of Oral Edaravone Administered in Subjects With ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT04220190|RAPA-501 Therapy for ALS|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT04248465|An Efficacy and Safety Study of Ravulizumab in ALS Participants|TERMINATED|PHASE3|INTERVENTIONAL","NCT04297683|HEALEY ALS Platform Trial - Master Protocol|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT04414345|HEALEY ALS Platform Trial - Regimen C CNM-Au8|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT04436497|HEALEY ALS Platform Trial - Regimen A Zilucoplan|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT04436510|HEALEY ALS Platform Trial - Regimen B Verdiperstat|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT04516096|A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT04569084|Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS|TERMINATED|PHASE3|INTERVENTIONAL","NCT04577404|Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)|COMPLETED|PHASE3|INTERVENTIONAL","NCT04615923|HEALEY ALS Platform Trial - Regimen D Pridopidine|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT04745299|Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04768972|FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT04944784|A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)|TERMINATED|PHASE3|INTERVENTIONAL","NCT04950933|The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT05021536|Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT05041582|SSRIs and TDCS Enhance Post-stroke Motor Recovery|UNKNOWN|PHASE3|INTERVENTIONAL","NCT05136885|HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT05151471|Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS|TERMINATED|PHASE3|INTERVENTIONAL","NCT05178810|Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis|COMPLETED|PHASE3|INTERVENTIONAL","NCT05193994|Triumeq in Amyotrophic Lateral Sclerosis|TERMINATED|PHASE3|INTERVENTIONAL","NCT05442775|A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)|TERMINATED|PHASE3|INTERVENTIONAL","NCT05568615|Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS|COMPLETED|PHASE3|INTERVENTIONAL","NCT05619783|Extension Study Evaluating The Safety And Tolerability of AMX0035|COMPLETED|PHASE3|INTERVENTIONAL","NCT05740813|HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT05753852|Open Label Extension of TUDCA-ALS Study|UNKNOWN|PHASE3|INTERVENTIONAL","NCT05842941|HEALEY ALS Platform Trial - Regimen G DNL343|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT05866926|Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis|TERMINATED|PHASE3|INTERVENTIONAL","NCT06008249|Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)|RECRUITING|PHASE3|INTERVENTIONAL","NCT06126315|Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS|RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT06391645|Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis|NOT_YET_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT06658977|RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial|TERMINATED|PHASE3|INTERVENTIONAL","NCT06719947|HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial|NOT_YET_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT06973629|Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT07082192|A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)|NOT_YET_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT07174492|Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients|NOT_YET_RECRUITING|PHASE3|INTERVENTIONAL","NCT07321860|This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling|NOT_YET_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT07322003|Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS|RECRUITING|PHASE3|INTERVENTIONAL","NCT07325591|Efficacy and Safety of Tazbentetol in ALS Participants|NOT_YET_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT07410806|HEALEY ALS Platform Trial - Regimen I NUZ-001|ENROLLING_BY_INVITATION|PHASE2/PHASE3|INTERVENTIONAL","NCT00004771|Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease|COMPLETED|PHASE2|INTERVENTIONAL","NCT00005674|Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]|COMPLETED|PHASE2|INTERVENTIONAL","NCT00005766|Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis|COMPLETED|PHASE2|INTERVENTIONAL","NCT00036413|A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis|COMPLETED|PHASE2|INTERVENTIONAL"]}]}